Infinant Health

Infinant Health is a private, clinical-stage biotech company spun out from the University of California, Davis, focusing on the critical window of infant gut microbiome development. Its lead program, INF108, is a next-generation drug strain of B. infantis designed to prevent necrotizing enterocolitis (NEC) in premature infants, representing a significant unmet medical need. The company also commercializes Evivo, a probiotic supplement for term infants, providing early revenue and real-world evidence. Founded on deep academic research into the interaction between breast milk and the infant microbiome, Infinant aims to restore beneficial bacteria lost in modern populations to build a foundation for lifelong health.

Proprietary platform based on the discovery and development of Bifidobacterium longum subsp. infantis (B. infantis) strains, particularly EVC001, which are highly efficient at consuming human milk oligosaccharides (HMOs) to colonize and modulate the infant gut microbiome for foundational health.

Infinant faces competition in the consumer probiotic space from companies like Culturelle and Gerber. Therapeutically, it competes with other microbiome-focused biotechs and the common use of off-label probiotic blends in NICUs for NEC prevention, though its targeted single-strain approach is a key differentiator.